Immunogenicity of Therapeutic Protein Aggregates

Journal of Pharmaceutical Sciences

Volumn 105, Issue 2, 2016, Pages 417-430

  Moussa, Ehab M ^a   Panchal, Jainik P ^a   Moorthy, Balakrishnan S ^a   Blum, Janice S ^b   Joubert, Marisa K ^c   Narhi, Linda O ^c   Topp, Elizabeth M ^a  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c AMGEN INC   (United States)

Author keywords

immune response; physicochemical properties; protein aggregation; proteins; regulatory science

Indexed keywords

DRUG ANTIBODY; HUMAN GROWTH HORMONE; HUMAN IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PROTEIN AGGREGATE; RECOMBINANT ERYTHROPOIETIN; CYTOKINE;

ADAPTIVE IMMUNITY; ANALYTIC METHOD; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BIOASSAY; COMPUTER MODEL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IN VIVO STUDY; INNATE IMMUNITY; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; T LYMPHOCYTE; ANIMAL; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); IMMUNOGENETICS; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; PROCEDURES;

ANIMALS; ANTIBODY FORMATION; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; IMMUNITY, CELLULAR; IMMUNOGENETIC PHENOMENA; LYMPHOCYTES; PROTEIN AGGREGATES;

EID: 84964494989     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2015.11.002     Document Type: Review

References (105)

1. E.Y. Chi, S. Krishnan, T.W. Randolph, and J.F. Carpenter Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation Pharm Res 20 9 2003 1325 1336
2. C.J. Roberts Non-native protein aggregation kinetics Biotechnol Bioeng 98 5 2007 927 938
3. H.C. Mahler, W. Friess, U. Grauschopf, and S. Kiese Protein aggregation: pathways, induction factors and analysis J Pharm Sci 98 9 2009 2909 2934
4. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: immunogenicity assessment for therapeutic protein products. 2014. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf. Accessed January 4, 2016.
5. A.S. Rosenberg Effects of protein aggregates: an immunologic perspective AAPS J 8 3 2006 E501 E507
6. M.F. Bachmann, T. Fehr, G. Freer, H. Hengartner, and R.M. Zinkernagel Correlation of tolerogenicity of a viral antigen with its immunogenicity J Immunol 158 11 1997 5106 5111
7. R.Z. Dintzis, M.H. Middleton, and H.M. Dintzis Studies on the immunogenicity and tolerogenicity of T-independent antigens J Immunol 131 5 1983 2196 2203
8. V. Filipe, A. Hawe, H. Schellekens, and W. Jiskoot Aggregation and immunogenicity of therapeutic proteins W. Wang, C. Roberts, Aggregation of Therapeutic Proteins 2010 John Wiley & Sons, Inc Hoboken, NJ
9. W. Wang, S.K. Singh, N. Li, M.R. Toler, K.R. King, and S. Nema Immunogenicity of protein aggregates-concerns and realities Int J Pharm 431 1-2 2012 1 11
10. K.D. Ratanji, J.P. Derrick, R.J. Dearman, and I. Kimber Immunogenicity of therapeutic proteins: influence of aggregation J Immunotoxicol 11 2 2014 99 109
11. A. Hawe, M. Wiggenhorn, M. van de Weert, J.H. Garbe, H.C. Mahler, and W. Jiskoot Forced degradation of therapeutic proteins J Pharm Sci 101 3 2012 895 913
12. L.O. Narhi, Y. Jiang, S. Cao, K. Benedek, and D. Shnek A critical review of analytical methods for subvisible and visible particles Curr Pharm Biotechnol 10 4 2009 373 381
13. J.S. Philo A critical review of methods for size characterization of non-particulate protein aggregates Curr Pharm Biotechnol 10 4 2009 359 372
14. D.C. Ripple, and M.N. Dimitrova Protein particles: what we know and what we do not know J Pharm Sci 101 10 2012 3568 3579
15. S. Zölls, R. Tantipolphan, M. Wiggenhorn, and et al. Particles in therapeutic protein formulations, Part 1: overview of analytical methods J Pharm Sci 101 3 2012 914 935
16. M.L. Udan, D. Ajit, N.R. Crouse, and M.R. Nichols Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line J Neurochem 104 2 2008 524 533
17. M.K. Joubert, M. Hokom, C. Eakin, and et al. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses J Biol Chem 287 30 2012 25266 25279
18. Y. Luo, Z. Lu, S.W. Raso, C. Entrican, and B. Tangarone Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcgamma receptors MAbs 1 5 2009 491 504
19. S. Katayama, D. Chia, H. Nasu, and D.W. Knutson Increased Fc receptor activity in monocytes from patients with rheumatoid arthritis: a study of monocyte binding and catabolism of soluble aggregates of IgG in vitro J Immunol 127 2 1981 643 647
20. R.N. Germain, and D.H. Margulies The biochemistry and cell biology of antigen processing and presentation Annu Rev Immunol 11 1993 403 450
21. M.I. Yuseff, P. Pierobon, A. Reversat, and A.M. Lennon-Duménil How B cells capture, process and present antigens: a crucial role for cell polarity Nat Rev Immunol 13 7 2013 475 486
22. V. Rombach-Riegraf, A.C. Karle, B. Wolf, and et al. Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro PLoS One 9 1 2014 e86322
23. M. Ahmadi, C.J. Bryson, E.A. Cloake, and et al. Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics Pharm Res 32 4 2015 1383 1394
24. H.M. Dintzis, R.Z. Dintzis, and B. Vogelstein Molecular determinants of immunogenicity: the immunon model of immune response Proc Natl Acad Sci U S A 73 10 1976 3671 3675
25. M.F. Bachmann, U.H. Rohrer, T.M. Kündig, K. Bürki, H. Hengartner, and R.M. Zinkernagel The influence of antigen organization on B cell responsiveness Science 262 5138 1993 1448 1451
26. M.F. Bachmann, H. Hengartner, and R.M. Zinkernagel T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Eur J Immunol 25 12 1995 3445 3451
27. T. Fehr, M.F. Bachmann, E. Bucher, and et al. Role of repetitive antigen patterns for induction of antibodies against antibodies J Exp Med 185 10 1997 1785 1792
28. Q. Vos, A. Lees, Z.Q. Wu, C.M. Snapper, and J.J. Mond B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms Immunol Rev 176 2000 154 170
29. M.M. van Beers, M. Sauerborn, F. Gilli, V. Brinks, H. Schellekens, and W. Jiskoot Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice Pharm Res 27 9 2010 1812 1824
30. M. Sauerborn, M.M. van Beers, W. Jiskoot, and et al. Antibody response against Betaferon® in immune tolerant mice: involvement of marginal zone B-cells and CD4+ T-cells and apparent lack of immunological memory J Clin Immunol 33 1 2013 255 263
31. G. Kijanka, M. Sauerborn, L. Boon, H. Schellekens, and V. Brinks Development of ADA against recombinant human interferon beta in immune tolerant mice requires rapid recruitment of CD4(+) T cells, induces formation of germinal centers but lacks susceptibility for (most) adjuvants J Pharm Sci 104 2 2015 396 406
32. M. Christie, R.M. Torres, R.M. Kedl, T.W. Randolph, and J.F. Carpenter Recombinant murine growth hormone particles are more immunogenic with intravenous than subcutaneous administration J Pharm Sci 103 1 2014 128 139
33. A.H. Fradkin, O. Mozziconacci, C. Schöneich, J.F. Carpenter, and T.W. Randolph UV photodegradation of murine growth hormone: chemical analysis and immunogenicity consequences Eur J Pharm Biopharm 87 2 2014 395 402
34. V. Filipe, W. Jiskoot, A.H. Basmeleh, A. Halim, H. Schellekens, and V. Brinks Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice MAbs 4 6 2012 740 752
35. V. Bi, V. Jawa, M.K. Joubert, and et al. Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics J Pharm Sci 102 10 2013 3545 3555
36. J. Bessa, S. Boeckle, H. Beck, and et al. The immunogenicity of antibody aggregates in a novel transgenic mouse model J Pharm Res 32 7 2015 2344 2359
37. M. Shomali, A. Freitag, J. Engert, and et al. Antibody responses in mice to particles formed from adsorption of a murine monoclonal antibody onto glass microparticles J Pharm Sci 103 1 2014 78 89
38. A.J. Freitag, M. Shomali, S. Michalakis, and et al. Investigation of the immunogenicity of different types of aggregates of a murine monoclonal antibody in mice Pharm Res 32 2 2015 430 444
39. M. Shomali, S. Tanriverdi, A.J. Freitag, and et al. Dose levels in particulate-containing formulations impact anti-drug antibody responses to murine monoclonal antibody in mice J Pharm Sci 104 5 2015 1610 1621
40. C.S. Henney, and E.F. Ellis Antibody production to aggregated human gamma-G-globulin in acquired hypogammaglobulinemia N Engl J Med 278 21 1968 1144 1146
41. S. Barandun, P. Kistler, F. Jeunet, and H. Isliker Intravenous administration of human gamma-globulin Vox Sang 7 1962 157 174
42. W.V. Moore, and P. Leppert Role of aggregated human growth hormone (hGH) in development of antibodies to hGH J Clin Endocrinol Metab 51 4 1980 691 697
43. A. Seidl, O. Hainzl, M. Richter, and et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity Pharm Res 29 6 2012 1454 1467
44. J.C. Ryff Clinical investigation of the immunogenicity of interferon-alpha 2a J Interferon Cytokine Res 17 suppl 1 1997 S29 S33
45. A.V. Palleroni, A. Aglione, M. Labow, and et al. Interferon immunogenicity: preclinical evaluation of interferon-alpha 2a J Interferon Cytokine Res 17 suppl 1 1997 S23 S27
46. A. Bertolotto, F. Deisenhammer, P. Gallo, and P. Sölberg Sørensen Immunogenicity of interferon beta: differences among products J Neurol 251 suppl 2 2004 II15 II24
47. J.G. Barnard, K. Babcock, and J.F. Carpenter Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity J Pharm Sci 102 3 2013 915 928
48. H.D. Shukla, and P.M. Pitha Role of hsp90 in systemic lupus erythematosus and its clinical relevance Autoimmune Dis 2012 2012 728605
49. N. Casadevall, J. Nataf, B. Viron, and et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin N Engl J Med 346 7 2002 469 475
50. M.G. Jacquemin, and J.M. Saint-Remy Factor VIII immunogenicity Haemophilia 4 4 1998 552 557
51. E.F. Ellis, and C.S. Henney Adverse reactions following administration of human gamma globulin J Allergy 43 1 1969 45 54
52. E.W. Gelfand Intravenous immune globulin in autoimmune and inflammatory diseases N Engl J Med 367 21 2012 2015 2025
53. C.L. Christian Studies of aggregated gamma-globulin. I. Sedimentation, electrophoretic and anticomplementary properties J Immunol 84 1960 112 116
54. C.L. Christian Studies of aggregated gamma-globulin. II. Effect in vivo J Immunol 84 1960 117 121
55. M.E. Weksler, G. Bull, G.H. Schwartz, K.H. Stenzel, and A.L. Rubin Immunologic responses of graft recipients to antilymphocyte globulin: effect of prior treatment with aggregate-free gamma globulin J Clin Invest 49 8 1970 1589 1595
56. L.E. Underwood, S.J. Voina, and J.J. Van Wyk Restoration of growth by human growth hormone (Roos) in hypopituitary dwarfs immunized by other human growth hormone preparations: clinical and immunological studies J Clin Endocrinol Metab 38 2 1974 288 297
57. W. Jelkmann Recombinant EPO production - points the nephrologist should know Nephrol Dial Transplant 22 10 2007 2749 2753
58. I.C. Macdougall Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks Nephrol Dial Transplant 20 suppl 4 2005 iv9 iv15
59. H. Orbach, U. Katz, Y. Sherer, and Y. Shoenfeld Intravenous immunoglobulin: adverse effects and safe administration Clin Rev Allergy Immunol 29 3 2005 173 184
60. M.M. van Beers, W. Jiskoot, and H. Schellekens On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis J Interferon Cytokine Res 30 10 2010 767 775
61. TICSGoCM Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia N Engl J Med 330 12 1994 820 825
62. E. Hochuli Interferon immunogenicity: technical evaluation of interferon-alpha 2a J Interferon Cytokine Res 17 suppl 1 1997 S15 S21
63. M.K. Joubert, Q. Luo, Y. Nashed-Samuel, J. Wypych, and L.O. Narhi Classification and characterization of therapeutic antibody aggregates J Biol Chem 286 28 2011 25118 25133
64. A. Braun, L. Kwee, M.A. Labow, and J. Alsenz Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice Pharm Res 14 10 1997 1472 1478
65. S. Hermeling, L. Aranha, J.M. Damen, and et al. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b Pharm Res 22 12 2005 1997 2006
66. S. Hermeling, H. Schellekens, C. Maas, M.F. Gebbink, D.J. Crommelin, and W. Jiskoot Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation J Pharm Sci 95 5 2006 1084 1096
67. A.H. Fradkin, J.F. Carpenter, and T.W. Randolph Immunogenicity of aggregates of recombinant human growth hormone in mouse models J Pharm Sci 98 9 2009 3247 3264
68. V.S. Purohit, C.R. Middaugh, and S.V. Balasubramanian Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice J Pharm Sci 95 2 2006 358 371
69. D.S. Pisal, M.P. Kosloski, C.R. Middaugh, R.B. Bankert, and S.V. Balu-Iyer Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice J Pharm Sci 101 6 2012 2055 2065
70. R. Torosantucci, V. Brinks, G. Kijanka, and et al. Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin J Pharm Sci 103 5 2014 1367 1374
71. R.T. McCluskey, F. Miller, and B. Benacerraf Sensitization to denatured autologous gamma globulin J Exp Med 115 1 1962 253 273
72. C.E. Biro, and G. Garcia The antigenicity of aggregated and aggregate-free human gamma-globulin for rabbits Immunology 8 1965 411 419
73. D.W. Dresser Specific inhibition of antibody production. I. Protein-over loading paralysis Immunology 5 1962 161 168
74. H.N. Claman Tolerance to a protein antigen in adult mice and the effect of nonspecific factors J Immunol 91 1963 833 839
75. C.N. Gamble The role of soluble aggregates in the primary immune response of mice to human gamma globulin Int Arch Allergy Appl Immunol 30 5 1966 446 455
76. A. Sassen, E.H. Perkins, and R.A. Brown Immunogenic potency of human gamma-globulin in mice Immunology 14 2 1968 247 256
77. A.H. Fradkin, J.F. Carpenter, and T.W. Randolph Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins J Pharm Sci 100 11 2011 4953 4964
78. Q. Luo, M.K. Joubert, R. Stevenson, R.R. Ketchem, L.O. Narhi, and J. Wypych Chemical modifications in therapeutic protein aggregates generated under different stress conditions J Biol Chem 286 28 2011 25134 25144
79. H. Lebrec, M.B. Hock, J.S. Sundsmo, and et al. T-cell-dependent antibody responses in the rat: forms and sources of keyhole limpet hemocyanin matter J Immunotoxicol 11 3 2014 213 221
80. V. Filipe, I. Que, J.F. Carpenter, C. Löwik, and W. Jiskoot In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice Pharm Res 31 1 2014 216 227
81. S. Hermeling, W. Jiskoot, D. Crommelin, C. Bornaes, and H. Schellekens Development of a transgenic mouse model immune tolerant for human interferon Beta Pharm Res 22 6 2005 847 851
82. M.M. van Beers, M. Sauerborn, F. Gilli, V. Brinks, H. Schellekens, and W. Jiskoot Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice Pharm Res 28 10 2011 2393 2402
83. M.M. Van Beers, F. Gilli, H. Schellekens, T.W. Randolph, and W. Jiskoot Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene J Pharm Sci 101 1 2012 187 199
84. C.L. Kempton, and G.C. White How we treat a hemophilia A patient with a factor VIII inhibitor Blood 113 1 2009 11 17
85. V. Jawa, L.P. Cousens, M. Awwad, E. Wakshull, H. Kropshofer, and A.S. De Groot T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation Clin Immunol 149 3 2013 534 555
86. M.R. Daha, E.S.L.A. van, H.M. Hazevoet, and A. Kijlstra Degradation of soluble immunoglobulin aggregates in vitro by monocytes from normal subjects and from patients with systemic lupus erythematosus Scand J Immunol 16 2 1982 117 122
87. Z.D. Ling, H.J. Ziltener, B.T. Webb, and D.S. Matheson Aggregated immunoglobulin and Fc fragment of IgG induce IL-6 release from human monocytes Cell Immunol 129 1 1990 95 103
88. R.B. Weltzien, and J.S. Pachter Visualization of beta-amyloid peptide (Abeta) phagocytosis by human mononuclear phagocytes: dependency on Abeta aggregate size J Neurosci Res 59 4 2000 522 527
89. S. Telikepalli, H.E. Shinogle, P.S. Thapa, and et al. Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting J Pharm Sci 104 5 2015 1575 1591
90. A.S. De Groot, J. McMurry, and L. Moise Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates Curr Opin Pharmacol 8 5 2008 620 626
91. N.J. Agrawal, S. Kumar, X. Wang, B. Helk, S.K. Singh, and B.L. Trout Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions J Pharm Sci 100 12 2011 5081 5095
92. P.M. Buck, S. Kumar, X. Wang, N.J. Agrawal, B.L. Trout, and S.K. Singh Computational methods to predict therapeutic protein aggregation Methods Mol Biol 899 2012 425 451
93. V. Voynov, N. Chennamsetty, V. Kayser, B. Helk, and B.L. Trout Predictive tools for stabilization of therapeutic proteins MAbs 1 6 2009 580 582
94. O. Conchillo-Solé, N.S. de Groot, F.X. Avilés, J. Vendrell, X. Daura, and S. Ventura AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides BMC Bioinformatics 8 2007 65
95. G.G. Tartaglia, and M. Vendruscolo The Zyggregator method for predicting protein aggregation propensities Chem Soc Rev 37 7 2008 1395 1401
96. A. Trovato, F. Seno, and S.C. Tosatto The PASTA server for protein aggregation prediction Protein Eng Des Sel 20 10 2007 521 523
97. I. Walsh, F. Seno, S.C. Tosatto, and A. Trovato PASTA 2.0: an improved server for protein aggregation prediction Nucleic Acids Res 42 Web Server issue 2014 W301 W307
98. A.M. Fernandez-Escamilla, F. Rousseau, J. Schymkowitz, and L. Serrano Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins Nat Biotechnol 22 10 2004 1302 1306
99. S. Kumar, S.K. Singh, X. Wang, B. Rup, and D. Gill Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions Pharm Res 28 5 2011 949 961
100. S. Kumar, M.A. Mitchell, B. Rup, and S.K. Singh Relationship between potential aggregation-prone regions and HLA-DR-binding T-cell immune epitopes: implications for rational design of novel and follow-on therapeutic antibodies J Pharm Sci 101 8 2012 2686 2701
101. S. Bukofzer, J. Ayres, A. Chavez, and et al. Industry perspective on the medical risk of visible particles in injectable drug products PDA J Pharm Sci Technol 69 1 2015 123 139
102. S.K. Singh, N. Afonina, M. Awwad, and et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics J Pharm Sci 99 8 2010 3302 3321
103. J.S. Bee, T.J. Goletz, and J.A. Ragheb The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective J Pharm Sci 101 10 2012 3580 3585
104. H.C. Mahler, and W. Jiskoot Analysis of Aggregates and Particles in Protein Pharmaceuticals 2012 John Wiley & Sons Hoboken, NJ
105. C. Kalonia, O.S. Kumru, I. Prajapati, and et al. Calculating the mass of subvisible protein particles with improved accuracy using microflow imaging data J Pharm Sci 104 2 2015 536 547